Type 2 diabetes in latin America: recommendations on the flash glucose monitoring system

Vista sencilla de ítem
dc.contributor.authorKrakauer, Marcio
dc.contributor.authorGómez, Ana M.
dc.contributor.authorAlmeda-Valdes, Paloma
dc.contributor.authorManrique, Helard
dc.contributor.authorRuiz Morosini, María Lidia
dc.contributor.authorGodoy Jorquera, Gonzalo
dc.contributor.authorNunes Salles, João Eduardo
dc.contributor.authorSanhueza Costa, David
dc.contributor.authorde Azeredo Siqueira, Rodrigo
dc.contributor.authorFaradji, Raquel N.
dc.contributor.authorRincón Ramírez, Alex
dc.contributor.authorRé, Matías
dc.contributor.authorFériz Bonelo, Karen
dc.contributor.authorProietti, Adrián
dc.contributor.authorLavalle-González, Fernando J.
dc.date.accessioned2024-05-27T17:42:51Z
dc.date.available2024-05-27T17:42:51Z
dc.date.issued2024-12
dc.descriptionINDEXACIÓN: SCOPUS.
dc.description.abstractObjective: To establish recommendations through the consensus of a Latin American experts panel on the use of the flash glucose monitoring system (fCGM) in people living with type 2 diabetes mellitus (T2DM) regarding the benefits and challenges of using the fCGM. Methods: An executive committee of experts was created, comprised by a panel of fifteen physicians, including endocrinologists and internal medicine physicians, with expertise in management of adult patients with T2DM. The experts were from various countries: Colombia, Chile, Peru, Mexico, Argentina, and Brazil. The modified Delphi method was used, considering a consensus level of at least 80% of the participants. A seventeen-item instrument was developed to establish recommendations on the use of fCGM in patients with T2DM in Latin American. Results: The number of glucose scans recommended per day with the fCGM for patients managed with oral antidiabetic drugs or basal insulin was a median of 6 scans per day, and for those managed with multiple insulin doses, a median of 10 scans per day was recommended. Additionally, a holistic and individualized management approach was recommended, taking into account new treatment directions and identifying patients who would benefit from the use of the fCGM. Conclusion: Continuous use of the fCGM is recommended for people living with T2DM, regardless of their type of treatment. These metrics must be evaluated individually for each patient profile. © The Author(s) 2024.
dc.identifier.citationDiabetology and Metabolic Syndrome, Volume 16, Issue 1, December 2024, Article number 106
dc.identifier.doi10.1186/s13098-024-01343-7
dc.identifier.issn1758-5996
dc.identifier.urihttps://repositorio.unab.cl/handle/ria/57140
dc.language.isoen
dc.publisherBioMed Central Ltd
dc.rights.licenseCC BY 4.0 DEED Attribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectConsensus
dc.subjectFlash Continuous Glucose Monitoring System
dc.subjectType 2 Diabetes
dc.titleType 2 diabetes in latin America: recommendations on the flash glucose monitoring system
dc.typeArtículo
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Type-2-diabetes-in-latin-America-recommendations-on-the-flash-glucose-monitoring-systemDiabetology-and-Metabolic-Syndrome.pdf
Tamaño:
865.87 KB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS.
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FM - Artículos de Revista